SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: Wally Mastroly who wrote (683)3/27/1998 7:08:00 AM
From: Henry Niman  Respond to of 9523
 
A competitor for PFE's Droloxifene and CP-366,156 just entered the clinic. Last night LGND announced AHP's IND filing for TSE424.
TSE424 is a SERM that will compete with SBH's Idoxifene, LLY's Evista (Raloxifene). I have linked the press release to the AHP Alliance table at
home.att.net as well as the TSE424 Clinical Trials table at
home.att.net